生物学驱动的II期试验：分子选择的最佳模型是什么？ - Suppr

Suppr

超能文献

Biology-driven phase II trials: what is the optimal model for molecular selection?

作者信息

Andre Fabrice, Delaloge Suzette, Soria Jean-Charles

机构信息

L'Institut National de la Santé et de la Recherche Médicale U981, Institut Gustave Roussy, Villejuif, France.

出版信息

J Clin Oncol. 2011 Apr 1;29(10):1236-8. doi: 10.1200/JCO.2010.31.6877. Epub 2011 Feb 22.

DOI:10.1200/JCO.2010.31.6877

PMID:21343554

Abstract

摘要

相似文献

Biology-driven phase II trials: what is the optimal model for molecular selection?

J Clin Oncol. 2011 Apr 1;29(10):1236-8. doi: 10.1200/JCO.2010.31.6877. Epub 2011 Feb 22.

Randomized phase II trials: misleading and unreliable.

J Clin Oncol. 2010 Nov 1;28(31):e649-50; author reply e651-3. doi: 10.1200/JCO.2010.31.3254. Epub 2010 Sep 20.

[Methodological approaches of clinical studies with targeted therapies].

Bull Cancer. 2008 Feb;95(2):185-90. doi: 10.1684/bdc.2008.0575.

Personalized-medicine trials on the rise.

J Natl Cancer Inst. 2012 Oct 3;104(19):1425-6. doi: 10.1093/jnci/djs432. Epub 2012 Sep 24.

A strategic framework for novel drug development in multiple myeloma.

Br J Haematol. 2007 Jul;138(2):153-9. doi: 10.1111/j.1365-2141.2007.06641.x.

Criticism of tumor response criteria raises trial design questions.

J Natl Cancer Inst. 2006 Feb 15;98(4):232-4. doi: 10.1093/jnci/djj086.

Phase II clinical trials in oncology: are we hitting the target?

Expert Rev Anticancer Ther. 2010 Mar;10(3):427-38. doi: 10.1586/era.09.178.

Emerging approaches to target tumor metabolism.

Curr Opin Pharmacol. 2014 Aug;17:22-9. doi: 10.1016/j.coph.2014.07.001. Epub 2014 Jul 19.

Epistatic interactions and drug response.

J Pathol. 2014 Jan;232(2):255-63. doi: 10.1002/path.4265.

Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.

Cancer J. 2009 Sep-Oct;15(5):426-30. doi: 10.1097/PPO.0b013e3181b9c5d5.

引用本文的文献

Moving toward precision medicine to predict drug sensitivity in patients with metastatic breast cancer.

ESMO Open. 2024 Mar;9(3):102247. doi: 10.1016/j.esmoop.2024.102247. Epub 2024 Feb 23.

HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer.

Front Oncol. 2023 Apr 28;13:1151496. doi: 10.3389/fonc.2023.1151496. eCollection 2023.

F-labeled FGFR1 peptide: a new PET probe for subtype FGFR1 receptor imaging.

Front Oncol. 2023 Apr 27;13:1047080. doi: 10.3389/fonc.2023.1047080. eCollection 2023.

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study.

Front Oncol. 2021 Nov 4;11:744112. doi: 10.3389/fonc.2021.744112. eCollection 2021.

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.

Eur Respir Rev. 2021 Jul 20;30(161). doi: 10.1183/16000617.0294-2020. Print 2021 Sep 30.

Participant Attitudes Toward an Intensive Trial of Multiple Biopsies, Multidimensional Molecular Analysis, and Reporting of Results in Metastatic Triple-Negative Breast Cancer.

JCO Precis Oncol. 2017 Aug 16;1. doi: 10.1200/PO.17.00076. eCollection 2017.

Differential responses to kinase inhibition in FGFR2-addicted triple negative breast cancer cells: a quantitative phosphoproteomics study.

Sci Rep. 2020 May 14;10(1):7950. doi: 10.1038/s41598-020-64534-y.

Precision Medicine in Relapsed and Refractory Childhood Cancers: Single-center Experience, Literature Review, and Meta-analysis.

Rambam Maimonides Med J. 2018 Jul 30;9(3):e0019. doi: 10.5041/RMMJ.10342.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

Oncotarget. 2018 Jan 12;9(11):9741-9750. doi: 10.18632/oncotarget.24188. eCollection 2018 Feb 9.

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.

Oncotarget. 2017 Mar 8;8(33):55582-55592. doi: 10.18632/oncotarget.16029. eCollection 2017 Aug 15.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验